Comparative Study of Regional Nerve Blocks in Primary Cleft Palate Repair

November 12, 2026 updated by: Children's National Research Institute

This study will evaluate whether adding a suprazygomatic maxillary nerve block to the standard palatal nerve block improves pain control after cleft palate repair surgery in children. Participants will be randomly assigned to receive either the standard palatal block alone or the standard palatal block combined with a suprazygomatic maxillary nerve block. Both techniques use medications commonly used for pain management during surgery.

The purpose of this study is to determine whether the addition of the suprazygomatic maxillary nerve block reduces postoperative pain, decreases the need for opioid medications, and improves recovery after cleft palate repair. Researchers will compare pain scores, medication use, recovery outcomes, and any treatment-related complications between the two groups.

Information collected from this study may help identify the most effective regional anesthesia approach for children undergoing cleft palate repair and may improve postoperative pain management and patient recovery.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

144

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Albert Oh
  • Phone Number: 202-713-8856

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

9 months and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children undergoing primary cleft palate repair or secondary velopharyngeal insufficiency (VPI) surgery.
  • Eligible to receive regional anesthetic nerve blocks as part of the planned surgical procedure.
  • Parent or legal guardian able and willing to provide informed consent.
  • Participant meets all institutional and surgical criteria for undergoing the planned procedure.

Exclusion Criteria:

  • Known allergy, hypersensitivity, or contraindication to the study anesthetic medications.
  • Medical conditions that contraindicate regional anesthetic nerve block procedures.
  • Coagulopathy or bleeding disorder that would increase the risk of nerve block placement.
  • Active infection at or near the planned injection site.
  • Inability of parent or legal guardian to provide informed consent.
  • Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study assessments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Standard Palatal Nerve Block

Participants receive the standard palatal nerve block performed during cleft palate surgery.

Regional anesthetic block of the palate performed during cleft palate or velopharyngeal insufficiency surgery using local anesthetic. This procedure serves as the standard pain management approach and is intended to provide perioperative analgesia and reduce postoperative pain.

Experimental: Standard Palatal Nerve Block Plus Suprazygomatic Maxillary Nerve Block

Participants receive the standard palatal nerve block plus a suprazygomatic maxillary nerve block during cleft palate surgery.

Regional anesthetic block of the maxillary nerve performed via a suprazygomatic approach using local anesthetic in addition to the standard palatal nerve block. The procedure is intended to enhance perioperative analgesia, decrease postoperative pain, and reduce postoperative opioid requirements following cleft palate or velopharyngeal insufficiency surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Pain Scores Measured by the Face, Legs, Activity, Cry, Consolability (FLACC) Scale
Time Frame: Within the first 24 hours following surgery

Postoperative pain will be assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale following cleft palate repair or velopharyngeal insufficiency surgery. The FLACC scale rates five behavioral categories (Face, Legs, Activity, Cry, and Consolability) from 0 to 2 each, for a total score ranging from a minimum of 0 to a maximum of 10. Higher scores indicate more pain and therefore a worse outcome. Pain scores will be compared between participants receiving a standard palatal nerve block and those receiving a standard palatal nerve block plus a suprazygomatic maxillary nerve block to evaluate the effectiveness of the additional regional anesthesia technique.

Within the first 24 hours following surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Opioid Consumption
Time Frame: Within the first 24 hours following surgery

Total postoperative opioid medication use will be recorded and compared between participants receiving a standard palatal nerve block and those receiving a standard palatal nerve block plus a suprazygomatic maxillary nerve block. This outcome will assess whether the additional regional anesthesia technique reduces the need for opioid analgesics following surgery.

Within the first 24 hours following surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 16, 2026

Primary Completion (Estimated)

December 16, 2027

Study Completion (Estimated)

December 16, 2028

Study Registration Dates

First Submitted

October 19, 2026

First Submitted That Met QC Criteria

October 19, 2026

First Posted (Actual)

October 23, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared with researchers outside of the study team. Data collected for this study contain protected health information and were obtained under informed consent and institutional review board requirements that do not include plans for external sharing of individual participant-level data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe